rich 1.0 FDA approvals, biotech acquisitions, and clinical trial updates are shaping today’s biopharma landscape. This episode of The BioPharm Brief covers the first approved PROTAC therapy for breast cancer, UCB’s planned acquisition of Candid Therapeutics, and new clinical data from Takeda Pharmaceutical Company in primary immunodeficiency. The BioPharm Brief https://audioboom.com/channels/5167274-the-biopharm-brief Audioboom https://audioboom.com 480 95 https://audioboom.com/i/43629171/600x600/c 600 600 <iframe width="100%" height="95" src="https://embeds.audioboom.com/posts/8899169/embed?v=202301" style="background-color: transparent; display: block; padding: 0; width: 100%" frameborder="0" allowtransparency="allowtransparency" scrolling="no" title="Audioboom player" allow="autoplay" sandbox="allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation"></iframe>